For instance, while prior studies found the degree of blood pressure lowering with ACEI or ARB use was greater in Whites than in Blacks [50] leading to low use of ACEI/ARBs in Blacks, the African American Study of Kidney Disease and Hypertension demonstrated that inhibition of the renin-angiotensin-aldosterone system was the most effective class of blood pressure therapy in improving CKD and mortality outcomes in Blacks with hypertension-related CKD [51], and has led to an improvement in the practice of low ACEI/ARB use in Blacks. This evidence concerns the gene REN and hypertensive disorder.